pSivida secure additional German Listings Berlin, Munich & Stuttgart

pSivida Limited (ASX: PSD) is pleased to announce that the company's applications

for listing on the Berlin, Munich and Stuttgart Stock Exchanges have met all the

admission requirements.

pSivida will trade under the ticker symbol PSI and the German securities code (WKN)

358705. pSivida will continue to trade on the Australian and Frankfurt Stock

Exchanges.

pSivida Managing Director Mr Gavin Rezos said, "These additional German listings

will serve to further increase the profile of pSivida with both institutional and retail

investors in Germany and across Europe. It provides investors abroad with the

opportunity to invest in the development and commercialisation of BioSilicon TM , while

also enhancing pSivida’s existing shareholder base and corporate visibility in these

key regions."

Berlin

The Berlin Stock Exchange has recently joined forces with the NASDAQ Europe and

has the largest market for offshore securities in the world with over 60 countries

represented. This unique variety provides the Berlin Stock Exchange with an

unrivaled position, both in Germany and internationally.

Munich

The Munich Stock Exchange is the third largest exchange in Germany and is based

on the new trading system MAX-ONE and favours a market model which is well

established at the New York Stock Exchange.

Stuttgart

The market model of the Stuttgart Stock Exchange has been designed to ensure

private investors receive comprehensive and personal service, combining application

of state-of-the-art technology and the personalised service of the order book

specialist.

Mr Rezos added, "European investors are trading foreign shares more and more

often and in increasing volumes. We are pleased to have secured these additional

listings and believe it reflects the support shown by those in the investment

community in Europe, following strong German institutional interest.”

pSivida recently signed a Licensing Agreement with German research agency

Forschungszentrum Jülich GmbH for the use of its porous silicon optical mirror

technology to develop and commercialise BioSilicon TM optical mirrors as an in-vivo

diagnostic device. Germany remains a key region of scientific and financial

significance for pSivida with the company expecting to undertake further

collaborations in Germany, particularly in the area of Diagnostics.